DAS181

Status
Phase 3
Condition
COVID-19
Intervention Type
Inhaled Drug
Funder Type
Industry

Drug Details

DAS181 is an inhaled sialidase.

Study Purpose

This study will seek to enroll immunocompromised patients with Lower Tract parainfluenza infection. It also contains a sub-study to enroll patients with severe COVID-19.


Find a Clinical Trial

 

footer_txt_bblBook a PFF Ambassador for your event.   Call 844.TalkPFF >